GRAPPA Meeting, Oct. 16, 2004 San Antonio, Texas Patient Global Question Alberto Cauli Rheumatology Division University of Cagliari, Italy Director Prof.

Slides:

Advertisements

Similar presentations

Patients with Rheumatoid Arthritis in Comparison to Other Connective Tissue Diseases Are Mostly Influenced by Concomitant Fibromyalgia Tomš J, Daňková.

Advertisements

Journal Club General Medicine C- 4/3/14

® Introduction Low Back Pain and Physical Function Among Different Ethnicities Adelle A Safo, Sarah Holder DO, Sandra Burge PhD The University of Texas.

Table 1. Comparison between the provisional diagnosis based on the proforma versus final diagnosis Early arthritis Rheumatoid arthritis 3 6 Psoriatic.

PROSPECTIVE OBSERVATIONAL MULTICENTER STUDY ON THE MANAGEMENT OF INTERMEDIATE CORONARY STENOSES: The Functional or morphological Lesion Assessment for.

Dr. M. Talebpour Advanced Laparoscopic Fellowship Tehran Medical University.

Measuring Signs and Symptoms in Rheumatoid Arthritis David R. Karp, MD, PhD Chief, Rheumatic Diseases UT Southwestern Medical Center David R. Karp, MD,

What is Body Mass Index (BMI) What is Body Mass Index (BMI)

The Impact of IMMPACT Bob A. Rappaport, M.D. Director Division of Anesthesia, Analgesia and Rheumatology Products Center for Drug Evaluation and Research.

A randomized, double-blind study on MD-knee versus HA in patients affected by knee OA: preliminary data from the JOINT study Umberto Massafra Dep of Rheumatology,

GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Philip Mease MD.

Dermatologist’s Role in Managing Psoriatic Arthritis Steven R. Feldman, MD, PhD Professor of Dermatology, Pathology & Public Health Sciences Wake Forest.

Copyright 4S Dawn 2002 Dawn AC Benchmarking Mark Ainsworth 4S Dawn Clinical Software Mark Ainsworth 4S Dawn Clinical Software.

Safeguarding the Public. It includes all the medical services, the ways in which individuals pay for medical care, and programs aimed toward preventing.

British Association of Dermatologists’ Biologic Intervention Register (BADBIR) Update November 2007.

Acute Effects of Prolong Short-Duration Stretching in Lunge Position and Using Wedge Stretching on Gastrosoleus Extensibility in Women with Gastrosoleus.

 The Juvenile Arthritis Foot Disability Index (JAFI) (Andre et al, 2004) was the primary outcome measure of the impact of JIA on the foot.  The Child.

Jaw Pain: Characteristics and Prevalence in Fibromyalgia and other Rheumatic Disorders Robert S. Katz 1, Frederick Wolfe 2. 1 Rush University Med Center,

Rehabilitation Teaching and Research Unit, Wellington School of Medicine and Health Sciences Outcome measures in psoriatic arthritis Preliminary identification.

PsA: Review of Available Assessment Instruments and Lessons from Trial Results Part II Christian Antoni Friedrich Alexander University Erlangen-Nürnberg.

Washington State Department of Social & Health Services – Division of Behavioral Health and Recovery - PRI One Department Vision Mission Core set of Values.

Maxime DOUGADOS Paris-Descartes University, Medicine Faculty; UPRES EA-4058; AP-HP, Cochin Hospital, Rheumatology B Dpt PARIS, France Status versus Changes:

Catherine Kober Margaret Johnson Martin Fisher Caroline Sabin On behalf of UK-CHIC BHIVA/BASHH Manchester 2010 Non-uptake of HAART among patients with.

Group for Research and Assessment in Psoriasis and Psoriatic Artritis PGA/VAS Patient and Physician Perception of disease in Psoriatic Arthritis (3PPsA)

Core Outcome Domains for Eczema – Results of a Delphi Consensus Project Introduction Eczema is a chronic, relapsing, inflammatory skin disorder that affects.

Effect of hydrotherapy in the rehabilitative treatment of Multiple Sclerosis (MS) Volanti P, Scialabba G, De Cicco D. Neurorehabilitation Unit Fondazione.

THE SURVEY OF PATIENTS’ PERCEPTION AND UNDERSTANDING OF ORAL ANTICOAGULATION THERAPY Author: Fülöp Zsolt Zoltán, coauthors: Drágus Emőke, Elekes Andrea.

GRAPPA research committee Philip Helliwell. History Steering committee in March 2005 received an application for funds to support a research project No.

This Outcome Report is based on data from patients who completed a Functional Restoration Programme (FRP) at the RealHealth Treatment Centre in Coventry.

OMERACT 8 PsA Module Co-Chairs Dafna Gladman and Philip Mease Steering Committee Alice Gottlieb, Philip Helliwell, Arthur Kavanaugh, Gerry Krueger, Peter.

Psoriatic Arthritis Workshop OMERACT May 14 th, 2004 Steering Committee Dafna Gladman, Philip Mease, Gerald Krueger, Désirée van der Heijde, Christian.

Treating Chronic Pain in Adolescents Amanda Bye, PsyD, Behavioral Medicine Specialist Collaborative Family Healthcare Association 15 th Annual Conference.

Evaluating A Systemic Therapy Psoriasis 1.Efficacy 2.Safety 3.Labeling.

EFFICACY OF SPA THERAPY IN RHEUMATOID ARTHRITIS-A RANDOMISED CONTROLLED CLINICAL STUDY Mine Karagülle Department of Medical Ecology and Hydroclimatology.

Another Perspective on PRO Content in Clinical Practice Ron D. Hays, Ph.D. University of California, Los Angeles June 25, 2007.

Saving time and improving care with a multidimensional health assessment questionnaire: 10 practical considerations T Pincus, Y Yazici, M Bergman J Rheumatol.

OMERACT 8 PsA Module Co-Chairs Dafna Gladman and Philip Mease Steering Committee Alice Gottlieb, Oliver FitzGerald, Philip Helliwell, Arthur Kavanaugh,

1 Assessing Disease Activity Janice Booth Rheumatology Nurse Practitioner January 2012.

Spondyloarthropathies. Introduction Spondyloarthropathy (Spondloarthritis) – Term for a group of chronic diseases – Affecting the joints of the spine.

Group for Research and Assessment in Psoriasis and Psoriatic Artritis PGA/VAS Patient and Physician Perception of disease in Psoriatic Arthritis (3PPsA)

OMERACT Workshop Outcome Measures in Psoriatic Arthritis

How To Design a Clinical Trial

Four Peas In A Pod A Team Approach to Patient Care Stacey Nickoloff D.O., Rujuta Gandhi, M.D., Mussarat Bukhari M.D., Elyas Parsa D.O., Munira Bhabhrawala.

Outcome Measures in PsA Philip Mease MD Seattle, WA.

Psoriatic Arthritis Workshop Part 2 OMERACT May 15 th, 2004 Steering Committee Dafna Gladman, Philip Mease, Gerald Krueger, Désirée van der Heidje, Christian.

Efectivness of Spa Therapy in Severe Knee Osteoarthritis; Randomize Controlled Trial Mine Karagülle,MD Istanbul, Turkey.

Module 9 Recording and reporting culture results Exercise 1.

DOCUMENTATION FOR MEDICAL STUDENTS Balasubramanian Thiagarajan.

OMERACT 8 PsA Module Proposal Submitted by: Dafna Gladman and Philip Mease.

GRAPPA Committee Reports and Outcome measures Dafna D. Gladman, MD, FRCPC Professor of Medicine, University of Toronto Director, PsA Program, University.

Psoriatic Arthritis Workshop OMERACT 7 Steering Committee Dafna Gladman, Philip Mease, Gerald Krueger, Désirée van der Heijde, Christian Antoni, Philip.

Introduction to the Model for Improvement How to Get Started with Quality Improvement Teams The Quality Academy Tutorial 12.

Efficacy of Colchicine When Added to Traditional Anti- Inflammatory Therapy in the Treatment of Pericarditis Efficacy of Colchicine When Added to Traditional.

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis R1 신가영 / Modulator Prof. 이연아 N Engl J Med 2015; 373: Philip J.

Acceptable changes in quality attributes of glycosylated biopharmaceuticals

Patients were considered not in MDA (MDA−) with a score of 0, 1, 2, 3 or 4 points and in MDA (MDA+) with a score of 5, 6 or 7 points.

Diacerein orphan drug development for epidermolysis bullosa simplex: A phase 2/3 randomized, placebo-controlled, double-blind clinical trial Verena Wally,

Perspectives in Psoriasis: Assessing Treatment Efficacy—Which Measures, What Do They Tell Us?

IL-17 Inhibitors in the Management of Psoriatic Disease

Figure 3 Simplified EULAR and GRAPPA

Figure 2 Simplified EULAR and GRAPPA

Responsibilities and Duties of Members and Staff

Figure 1 Simplified EULAR and GRAPPA

Differences in the temporal dynamics of daily activity between chronic pain patients and healthy controls P. Montoya1, P. Geha2, M. Baliki2, A. V. Apkarian2,

Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR50, (B) CDAI LDA and (C) HAQ-DI

OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. OR for baseline predictors of MDA at weeks 12,

Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.

Clinical response in patients with early and established RA at month 24. *p

Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: A pooled analysis of the Phase 3 VOYAGE 1 and VOYAGE.

(A) JIA-ACR30/50/70/90 response rates by visit in part 1.

Presentation transcript:

GRAPPA Meeting, Oct. 16, 2004 San Antonio, Texas Patient Global Question Alberto Cauli Rheumatology Division University of Cagliari, Italy Director Prof. A Mathieu B*2709

Proposal for the Assessment of Patients and Physicians perception of Joints & Skin involvement in PsA through VAS DCART (Delphi) ranked highest: JC, x-ray, patient global, pain, function, acute phase res. GRAPPA meeting in Berlin 6 VASs. Are they too many? Is it worth? What exactly do they tell us? The aim of the proposed exercise is to test the information given by the different VASs.

PsA Patients VASs Please place a mark on each line below to indicate your answer to each question relating to the past week (or 3 days?/ or day of assessment?) Global In all the ways in which your PSORIASIS and ARTHRITIS, as a whole, affects you, how would you rate the way you feel at this time? (10 cm line) (from “wellness” to “the worse I can feel”) Joints In all the ways your ARTHRITIS affects you, how would you rate the way you feel at this time? (10 cm line) Skin In all the ways your PSORIASIS affects you, how would you rate the way you feel at this time? (10 cm line)

Physician VAS Global How would you rate GLOBAL skin and joint disease in this patient? (10 cm line) (from quiet to very severe) Joints How would you rate JOINT disease in this PsA patient? (10 cm line) (from no inflammation to very severe) Skin How would you rate PSORIASIS in this PsA patient? (10 cm line) (from “clear” to “very severe”)

RECRUITMENT AND ASSESSMENT Any consecutive PsA patient that comes to the clinic regardless of disease activity or treatment ? The following data will be recorded at time 0, T1 (after 1 week) and T2 (after 3 months): Patient Global, Joint, Skin VAS Doctor Global, Joint, Skin VAS ACR joint count (68)* PASI (Dermatologist Static Global Assessment?) Sex, age, clinical subset, disease duration, job (manual, intellectual, contact with the public) Data analysis and discussion among GRAPPA members * As decided at the GRAPPA meeting in Berlin

Statistical analysis How many patients do we need? No pre-study to evaluate a sample of patients I have assumed that: changes in the score (T1-T2) will range from 0 to 5 cm and  = 1 cm In order to fulfill the primary aim (comparison of VASs only) we need at least 131 patients (recommended 200), to further analyse the data (JC, PASI, clinical subset, sex, age, job, disease duration) we may need more. The results will be statistically analysed as appropriate. The data will be discussed by the partecipating Colleagues and by all GRAPPA members through Big Mind Catalyst. A final vote will decide which VAS to be included in the assessment of PsA patients.